RxDoctor Payments Data

Rodel Banal, MD

Pulmonary Disease · Melbourne, FLNPI 1932422433

Payments from drug & device makers

$7,292in general payments, 2019–2025

Across 68 payments — averaging $107.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Pulmonx Corporation$1K
  • Actelion Pharmaceuticals US, Inc.$676
  • Veran Medical Technologies, Inc.$283
  • Boehringer Ingelheim$161
  • Philips North America LLC$124
  • plus $972 from 21 others

What the payments were for

  • Travel & lodging$1,99727%
  • Food & beverage$2,28231%
  • Education$3,01341%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,292 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$260,622
Medicare patients
987
Services billed
2,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate14$187,454
Trelegy ElliptaFluticasone/Umeclidin/Vilanter133$109,851
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$28,994
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr31$19,474
Pirfenidone12$18,392
Spiriva RespimatTiotropium Bromide20$13,942
Breo ElliptaFluticasone/Vilanterol24$12,813
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$9,552
SymbicortBudesonide/Formoterol Fumarate20$8,602
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$6,556
Incruse ElliptaUmeclidinium Bromide13$4,988
Albuterol Sulfate HfaAlbuterol Sulfate88$3,411
Montelukast Sodium68$1,239
Ventolin HfaAlbuterol Sulfate13$1,012
Roflumilast11$414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$161$210,94947 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$99$147,126201 claims
AstraZenecaBreztri Aerosphere, Symbicort$64$37,59652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →